Ginkgo Bioworks Holdings DNA
NYSE DNA
$6.80 -0.14 (-2.09%)
As of: Sep 9, 2026 · 3:59 PM EDT

Ginkgo Bioworks Holdings (DNA) EBIT Margin Growth (3y) (2023 - 2026)

Analysis

Ginkgo Bioworks Holdings (DNA) EBIT Margin Growth (3y) (2023 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin Growth (3y) (Qtr)
1 Iqvia Holdings 44.06 Bn 42.11 Bn 1.44 Bn -247.00
2 Medpace Holdings 16.50 Bn 16.00 Bn 201.64 Mn 375.00
3 Charles River Laboratories International 13.77 Bn 13.62 Bn 452.07 Mn -362.00
4 Icon 12.62 Bn 11.69 Bn 479.29 Mn -369.00
5 Fortrea Holdings 1.68 Bn 1.51 Bn 139.20 Mn -218.00
6 Evotec SE 661.34 Mn 235.46 Mn - -
7 Ginkgo Bioworks Holdings 442.79 Mn 358.26 Mn 18.44 Mn -6,191.00
8 Champions Oncology 72.49 Mn 72.62 Mn 7.03 Mn 1,551.00
9 MindWalk Holdings 61.66 Mn 53.38 Mn 1.82 Mn 289.00
10 VivoSim Labs 1.47 Mn 1.47 Mn - -973,444.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -6,191.00
Mar 31, 2026 -9,917.00
Dec 31, 2025 2,303.00
Sep 30, 2025 75,460.00
Jun 30, 2025 29,930.00
Mar 31, 2025 18,924.00
Dec 31, 2024 89,826.00
Sep 30, 2024 -2,763.00
Jun 30, 2024 -25,928.00
Mar 31, 2024 -33,960.00
Dec 31, 2023 10,106.00
Sep 30, 2023 -25,797.00